» Articles » PMID: 38792716

What Do We Know About Cryptic Aspergillosis?

Overview
Journal Microorganisms
Specialty Microbiology
Date 2024 May 25
PMID 38792716
Authors
Affiliations
Soon will be listed here.
Abstract

Cryptic species are increasingly recognized as pathogens involved in human disease. They are ubiquitarian fungi with high tenacity in their environment and can express various resistance mechanisms, often due to exposure to antifungal agents employed in agriculture and farming. The identification of such species is increasing thanks to molecular techniques, and a better description of this type of pathogen is granted. Nevertheless, the number of species and their importance in the clinical setting still need to be well studied. Furthermore, their cross-sectional involvement in animal disease, plants, and human activities requires a multidisciplinary approach involving experts from various fields. This comprehensive review aims to provide a sharp vision of the cryptic species, from the importance of correct identification to the better management of the infections caused by these pathogens. The review also accentuates the importance of the One Health approach for this kind of microorganism, given the interconnection between environmental exposure and aspergillosis, embracing transversely the multidisciplinary process for managing the cryptic species. The paper advocates the need for improving knowledge in this little-known species, given the burden of economic and health implications related to the diffusion of these bugs.

Citing Articles

Invasive Pulmonary Aspergillosis in Patients with HBV-Related Acute on Chronic Liver Failure.

Yuan M, Han N, Lv D, Huang W, Zhou M, Yan L J Fungi (Basel). 2024; 10(8).

PMID: 39194897 PMC: 11355146. DOI: 10.3390/jof10080571.

References
1.
Fortun J, Carratala J, Gavalda J, Lizasoain M, Salavert M, de la Camara R . [Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update]. Enferm Infecc Microbiol Clin. 2011; 29(6):435-54. DOI: 10.1016/j.eimc.2011.01.010. View

2.
Jallow S, Govender N . Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J Fungi (Basel). 2021; 7(3). PMC: 7996284. DOI: 10.3390/jof7030163. View

3.
Romero M, Messina F, Marin E, Arechavala A, Depardo R, Walker L . Antifungal Resistance in Clinical Isolates of spp.: When Local Epidemiology Breaks the Norm. J Fungi (Basel). 2019; 5(2). PMC: 6617206. DOI: 10.3390/jof5020041. View

4.
Varga J, Houbraken J, van der Lee H, Verweij P, Samson R . Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell. 2008; 7(4):630-8. PMC: 2292628. DOI: 10.1128/EC.00425-07. View

5.
Verweij P, Howard S, Melchers W, Denning D . Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009; 12(6):141-7. DOI: 10.1016/j.drup.2009.09.002. View